Status:
RECRUITING
Reboxetine for Sleep Apnoea After ENT Surgery
Lead Sponsor:
Flinders University
Collaborating Sponsors:
Flinders Medical Centre
Conditions:
Sleep Apnea, Obstructive
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) inc...
Eligibility Criteria
Inclusion
- Age \>18 years
- Undergoing elective upper airway surgery
- History of obstructive sleep apnoea (OSA)
Exclusion
- Clinically significant cardiac disease (e.g., arrhythmia, coronary artery disease, or cardiac failure)
- History of clinically significant urinary retention, bladder outlet obstruction, or benign prostatic hyperplasia
- Poorly controlled hypertension
- Epilepsy
- History of schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-V or International Classification of Disease 10th edition criteria
- History of attempted suicide or suicidal ideation within 1 year prior to screening, or current suicidal ideation
- Narrow angle glaucoma
Key Trial Info
Start Date :
August 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05978505
Start Date
August 10 2023
End Date
July 1 2025
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Flinders, Private and Public Hospitals and Flinders University
Bedford Park, South Australia, Australia, 5042